Skip to content
Global Locations
Contact Us
Search
About Us
History
Leadership
Mission and Values
Global Locations
What We Treat
Eye Care :
Dry Eye
Glaucoma
Other Eye Conditions
Neurosciences :
Blepharospasm
Cervical Dystonia
Strabismus
Upper Limb Spasticity
Obesity Intervention
Medical Aesthetics :
Breast Aesthetics
Facial Aesthetics
Medical Dermatology :
Acne
Psoriasis
Severe Primary Axillary Hyperhidrosis Inadequately Managed with Topical Agents
Other Skin Conditions
Urologics :
Urinary Incontinence
Products
Ophthalmic Pharmaceuticals
Neurosciences
Obesity Intervention
Medical Aesthetics: Breast and Facial
Medical Dermatology
Urologics
Product Prescribing and Labeling Information
Patent Notices
R&D
Pipeline
Corporate Research Collaborations
Allergan Clinical Trials
Excellence in Research
Newsroom
Fast Facts
Press Releases
Investors
Earnings Releases
Stock Information
Financial Reports
Non-GAAP Financial Reconciliation
Corporate Governance & Certificates
Webcasts & Transcripts
Analyst Coverage
Shareholder Information
Contact Information
Responsibility
Patient Safety and Product Quality
Compliance and Ethics
Allergan Foundation
Patient Resources
Physician Resources
Professional Affiliations
Unrestricted Educational Grants
Political Contributions
California Supply Chain Disclosure
Health Care Provider Partnerships & Payments
Commitment to Human Rights Charters
Environmental Health and Safety
Animal Testing
Careers
Mission and Values
Total Rewards
Recognizing Excellence
Global Careers at Allergan
Job Search
My Candidate Profile
FAQ
-->-->-->-->
In this Section:
Overview
Pipeline
Corporate Research Collaborations
Allergan Clinical Trials
Excellence in Research
Related Links:
Allerganclinicaltrials.com
Pipeline
Ophthalmics
Product
Indication
Industry Partners
Status
Unit Dose GANFORT™ (EU)
Glaucoma
-
Filed
Alpha II Agonist - NCE
Glaucoma
-
Pre-Clinical
Bimatoprost Sustained Release
Glaucoma
-
Phase 2
OZURDEX
®
Diabetic Macular Edema
-
Phase 3
RESTASIS
®
(EU)
Ocular Surface Disease
-
Phase 3
RESTASIS
®
X
Ocular Surface Disease
-
Phase 2
NOVADUR
®
(Brimonidine)
Retinal Diseases
-
Phase 2
AGN 208397
Retinal Diseases
-
Phase 2
AGN 150998 (Anti-VEGF DARPin
®
)
Age-Related Macular Degeneration
-
Phase 2
Anti-VEGF/PDGF-B DARPin
®
Age-Related Macular Degeneration
-
Pre-Clinical
TKI
Age-Related Macular Degeneration
-
Pre-Clinical
Neurology/Pain
Product
Indication
Industry Partners
Status
LEVADEX
®
Migraine - Acute Therapy
MAP Pharmaceuticals, Inc.
Filed
BOTOX
®
Juvenile Cerebral Palsy
-
Phase 3
TEM
Pain
-
Phase 2
BOTOX
®
Osteoarthritis Pain
-
Phase 2
Urology
Product
Indication
Industry Partners
Status
SER-120
Nocturia
Serenity Pharmaceuticals, LLC
Phase 3
Pharmaceutical Dermatology
Product
Indication
Industry Partners
Status
BOTOX
®
Cosmetic (U.S. & EU)
Crows Feet Lines
-
Filed
LATISSE
®
(EU National Agencies)
Lash
-
Phase 3
LATISSE
®
Brow
-
Phase 2
Bimatoprost
Scalp
-
Phase 2
Oxymetazoline (Vicept V-101)
Rosacea
-
Phase 2
Medical Devices (Aesthetics/Health)
Product
Indication
Industry Partners
Status
JUVÉDERM
®
VOLUMA™ (U.S.)
Facial Aesthetics
-
Filed
JUVÉDERM
®
Volbella™ (U.S.)
Facial Aesthetics
-
Feasibility
JUVÉDERM
®
Volift™ (U.S.)
Facial Aesthetics
-
Feasibility
Follow Allergan, Inc. on:
Research Centers of Excellence
Allergan's R&D facilities contain state-of-the-art laboratories to support early stage, leading-edge discovery research. They include specialized areas for molecular biology, neuromodulator research, high throughput screening and medicinal chemistry. In 2004, we opened the Herbert Research Center (pictured above) to accommodate the tremendous growth of our new drug discovery programs, and to enhance our ability to more rapidly move new medicines into the clinic that satisfy unmet medical needs and enable patients to live life to its fullest potential.